44 results about "Blood platelet counts" patented technology

Provided is a method for assisting in grasping the status of platelet activation, by developing a biomarker that more accurately reflects platelet activation in vivo, said method being usable in testing for thrombotic hemostatic diseases. The method for assisting in grasping the status of platelet activation comprises (1) measuring the concentration of soluble CLEC-2 and a platelet count in a sample obtained from a subject, and (2) calculating a value of [soluble CLEC-2 concentration] / [platelet count] by dividing the soluble CLEC-2 concentration by the platelet count. If desired, the method may further comprise (3) comparing the value with a value of [soluble CLEC-2 concentration] / [platelet count] obtained by using samples from healthy persons.

The present invention provides a pharmaceutical composition for use in a method of treating pulmonary arterial hypertension (PAH). [Solution] A pharmaceutical composition for use in a method for treating pulmonary arterial hypertension (PAH) in a patient in need, comprising an ActRIIA fusion protein, wherein the ActRIIA fusion protein is (i) ActRIIA polypeptide containing a specific amino acid sequence, (ii) Fc domains containing an amino acid sequence that is at least 95% identical to a specific amino acid sequence, (iii) comprising a linker domain located between the ActRIIA polypeptide and the Fc domain, Herein, the ActRIIA fusion protein is administered in a first dose of 0.3 mg / kg and a second dose of 0.7 mg / kg, wherein the second dose is administered after confirming that the patient has an acceptable hemoglobin level and / or platelet count, in a pharmaceutical composition.

The invention relates to a method for constructing a preeclampsia prediction model by using clinical laboratory data and a related application thereof. Specifically, the preeclampsia risk prediction model is constructed based on a plurality of clinical indexes of pregnant women, a plurality of clinical laboratory data and insulin growth binding factor binding protein 1 and / or placental growth factors. The clinical laboratory data comprises leukocyte count and / or urine protein, and further comprises any one or combination of platelet count, monocyte proportion, glutamic-straw / glutamic-pyruvic transaminase ratio, glutamyltranspeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Meanwhile, the sensitivity of the prediction model is 88.0% when the specificity of early eclampsia is 85.04% and the sensitivity of the prediction model is 62.5% when the specificity of late eclampsia is 85.04% in a complete independent verification set, and the detection performance of the prediction model is higher than that of the current detection performance.

The invention discloses a clinical prediction model for the dyslipidemia probability of a child hepatolenticular degeneration patient and a design method, and belongs to the technical field of medical information. The clinical prediction model comprises an input module for receiving patient parameter indexes consisting of an age group (Age group, lt, 10 years old or more), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), homocysteine (Hcy), superoxide dismutase (SOD) and platelet count (PLT); the processing module is connected with the input module and calculates the prediction probability of the patient according to the model, and the output module is connected with the processing module and outputs the probability of dyslipidemia of the child hepatolenticular degeneration patient, which is finally obtained by the clinical prediction model. The prediction model established by the invention has good distinction degree, calibration degree and clinical practicability, has relatively high accuracy, and can be conveniently used for early recognition and risk prediction of dyslipidemia caused by hepatolenticular degeneration of children.

The invention relates to a cell image analyzer, a sample analysis system and a cell image analysis method. The cell image analyzer comprises: an imaging device for shooting a cell image; the bearing device is used for bearing the blood smear on which the blood film is applied; the control device is used for controlling the blood smear and the imaging device to move relative to each other, so that a plurality of shooting points in a target area of the blood film are respectively positioned in a visual field of the imaging device, and controlling the imaging device to shoot images of the shooting points in the visual field of the imaging device so as to obtain target cell images of the plurality of shooting points in the target area; the image analysis device is used for identifying platelets in the multiple target cell images and acquiring actual platelet distribution information of the blood membrane based on the platelets identified in the multiple target cell images and the shooting positions of the multiple target cell images in the smearing direction; and based on the actual platelet distribution information, acquiring platelet count and / or judging whether the to-be-detected blood sample is a platelet aggregation sample or not.

The present invention relates to a method of treating idiopathic thrombocytopenic purpura (ITP) in a patient with ITP, comprising: (a) administering romiplostim weekly to the patient; (b) increasing the weekly dose until a platelet count of at least approximately 50 to 200 x 10⁹ / L is achieved; (c) decreasing the weekly dose of romiplostim if the platelet count remains > 200 x 10⁹ / L for two consecutive weeks; (d) permanently discontinuing romiplostim if the platelet count remains > 200 x 10⁹ / L for two consecutive weeks when the weekly dose is 1 µg / kg or the platelet count is > 400 x 10⁹ / L; and (e) if a platelet count > 200 x 109 / L is achieved during the first 4 to 12 weeks of treatment, maintain a treatment-free period of at least approximately 24 weeks during which the patient does not receive romiplostim.

The invention relates to tinostamustine for use in the treatment of lymphoma or a T-cell malignant disease. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patient's platelet count.

This disclosure provides processes for preparing cryopreserved platelets, compositions comprising frozen platelets in cryopreservation media, and collections of cryocontainers comprising cryopreserved platelets. In some embodiments, for example at DMSO concentrations, processes for preparing cryopreserved platelets from a platelet pool of two or more donors are provided herein to provide a collection of cryopreserved platelets with improved vial-to-vial and lot-to-lot consistency. Collections of cryocontainers comprising cryopreserved platelets, each having a biomolecular profile representing two or more platelet donors, are also provided herein. Furthermore, compositions comprising frozen platelets are provided herein, which, when stored at a temperature in the range of -10°C to -30°C for at least one month, are capable of yielding a platelet count of at least 1.0 × 10¹¹ / 35 ml of composition, and other enumerated properties.

The invention relates to the technical field of medicines, and particularly discloses application of ipropam in preparation of a medicine for treating immune thrombocytopenic purpura. Aiming at the clinical problem that the condition of a patient with refractory recurrent immune thrombotic thrombocytopenic purpura (iTTP) still progresses after the treatment of plasma exchange combined with hormone, repatumab and immune globulin is invalid, the complement abnormal activation marker of the patient is detected to be increased, which indicates that the complement bypass way participates in disease recurrence refractory; ipropam is combined with plasma exchange, hormone and rituximab for treatment. Results show that the hemoglobin and platelet count is significantly increased after treatment for 5 days, mental symptoms are improved in 9 days, creatinine returns to normal in 11 days, ADAMTS13 activity is less than 0.2 IU / dL in 14 days, an inhibitor turns negative, and ADAMTS13 activity, hemoglobin and platelet return to normal in the fifth week. According to the application, it is proved for the first time that ipropam can effectively reverse the pathological process of refractory iTTP by inhibiting complement bypass pathway activation, and a new treatment strategy is provided for the disease.

The embodiments of the present application relate to a platelet counting method and a blood cell analyzer. The method comprises: aspirating a blood sample to be tested; mixing one portion of said blood sample with a diluent to prepare a first test sample, and mixing the other portion of said blood sample with a hemolytic agent and fluorescent dye to prepare a second test sample; performing impedance measurement on the first test sample, in order to obtain an electrical signal of the first test sample; performing optical measurement on the second test sample, in order to obtain at least one optical signal from among a scattered light signal and a fluorescent light signal of the second test sample; at least on the basis of the electrical signal of the first test sample, obtaining platelet distribution information of said blood sample; and at least on the basis of the pulse width of an optical signal among the at least one optical signal that corresponds to platelets in the second test sample, and the platelet distribution information, obtaining a platelet count value. Thus, an accurate platelet count can be obtained at a low cost.

Provided are apparatuses and methods that include imaging a blood sample that is a suspension of cells deposited in a sample chamber. The cells are allowed to settle in the sample chamber to form a monolayer of cells. At least one microscopic image of the monolayer of cells is acquired using a microscope (24) while the microscope is focused at a monolayer depth level, and a first platelet count of platelets that have settled within the monolayer is determined. Additional microscopic images of the sample are acquired while the microscope is focused at depth levels different from the monolayer depth level, and a second platelet count of platelets that are not settled within the monolayer is determined. An output is generated based on the first platelet count and the second platelet count. Other applications are also described.

The invention provides a model for predicting the risk of allergic reaction of a Wilson disease patient during copper expelling treatment, and belongs to the crossing field of clinical medicine and biological information technology. The risk prediction model comprises: an input module receiving patient parameter indexes composed of a sodium dimercaptopropanesulfonate injection dosage, a severe adverse drug reaction, a drug allergy history, a neutrophil count, a lymphocyte count, a ratio of neutrophil to lymphocyte, a ratio of platelets to lymphocyte, a leukocyte count, a urine copper level and a platelet count; the processing module is connected with the input module and is used for calculating the score and prediction probability of the allergic reaction during copper expelling treatment based on the parameter indexes of the patient; and the output module is connected with the processing module, and outputs the allergic reaction risk probability obtained by the risk prediction model during the copper expelling treatment of the Wilson disease patient. The risk prediction model can be conveniently used for early recognition and risk prediction of anaphylaxis of a Wilson disease patient during copper expelling treatment.

The invention provides an application of a flow detection reagent in a bleeding risk grade classification product of tumor diseases, and belongs to the field of biomedical detection. The invention provides a non-disease diagnosis method which comprises the following steps: S1, adding a flow type detection reagent into peripheral blood of a normal person for detection, collecting a ratio S / N result of positive group fluorescence intensity to negative group fluorescence intensity of an analysis marker, and establishing a reference interval; s2, collecting and treating a to-be-detected peripheral blood sample, detecting the to-be-detected sample by using a flow detection reagent and instrument parameters which are the same as those in S1, and collecting and analyzing an S / N result; and S3, comparing the S / N result of the S2 with the reference interval of the S1, and evaluating the bleeding risk. Compared with a traditional platelet counting method, the method has the advantages of rapidness, high specificity, high sensitivity, low required sample size and the like.

This invention discloses a predictive model for early fever and infection after CAR-T therapy. The equation for this predictive model is: P = 1 / (1 + e^(-3.23 + 0.017 × CRP + 0.003 × IL - 6 - 0.023 × platelet count - 8.048 × lymphocyte count - 1.241 × FCV + 1.6146 × neutropenia grade)); where P is the probability of infection. P < 0.20 is defined as low risk, classified as CRS; 0.2 ≤ P ≤ 0.6 is defined as medium risk, requiring further testing to determine whether it is infection or CRS; P > 0.6 is defined as high risk, classified as infection. This predictive model is used to predict the likelihood of infection in the first fever event after CAR-T therapy. By analyzing various clinical laboratory indicators and combining logistic regression analysis, the model screens out key predictive factors related to infection risk, ultimately establishing an efficient and easy-to-use predictive tool. This model can effectively predict the occurrence of infection, provide clinicians with guidance for early intervention, reduce unnecessary clinical testing, and optimize patients' treatment plans.

Citrate has been used as an anticoagulant because of its calcium chelation capability, but it may have unwanted off target metabolic and inflammatory effects; accordingly, alternative anticoagulants may have benefits compared with citrate. Diethylenetriamine pentaacetic acid (DTPA) is an octadentate chelator that is FDA-approved to treat plutonium, americium, and curium exposure by chelation. In this disclosure, it is demonstrated that a composition comprising DTPA, DPDA-1, functions effectively as an anticoagulant for the storage of whole blood, with an increased platelet count and improved viscoelastic properties compared with citrate composition, although DTPA-composition requires half of the amount of calcium to restore clotting function, which suggest DTPA composition's lowering the risk of post transfusion hypocalcemia in comparison to citrate transfusion. Therefore, DTPA-composition is presented here as an anticoagulant to preserve platelets.

A method for constructing a preeclampsia prediction model by using clinical laboratory data and the use thereof. Specifically, the preeclampsia risk prediction model is constructed on the basis of several clinical indexes of pregnant women, several pieces of clinical laboratory data, and insulin-like growth factor-binding protein 1 and / or placental growth factor. The several pieces of clinical laboratory data comprise white blood cell count and / or urine protein, and further comprise any one or a combination of platelet count, monocyte percentage, aspartate aminotransferase / alanine aminotransferase ratio, glutamyl transpeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Moreover, in a fully independent validation set, when the specificity of the prediction model for early-onset preeclampsia is 85.04%, the sensitivity is 88.0%, and when the specificity for late-onset preeclampsia is 85.04%, the sensitivity is 62.5%, outperforming the current detection performance.

The present invention refers to a new use of a composition comprising a calcimimetic for enhancing engraftment and lineage reconstitution of hematopoietic stem and progenitor cells (HSPCs) in hematopoietic cell transplantation (HCT) recipients, wherein before transplantation, said HSPCs are pre-treated in vitro ("primed") with a prostacyclin analogue and an adenylate cyclase sensitizer, and the composition is administered shortly before, or at the time of transplantation of said HSPCs, and after transplantation of said HSPCs. The invention further refers to a therapeutic combination comprising HSPCs and a calcimimetic and a method for enhancing engraftment capabilities of HSPCs.

The embodiment of the invention relates to a platelet counting method and a blood cell analyzer. The method comprises the following steps: adding a diluent and a fluorescent dye into a to-be-tested blood sample to obtain the to-be-tested blood sample; light measurement is conducted on the to-be-measured sample to obtain forward scattering light signals of all particles in the to-be-measured sample, and each forward scattering light signal comprises forward scattering light pulse intensity and forward scattering light pulse width; and obtaining a platelet count value of the to-be-tested blood sample at least based on the forward scattering light pulse intensity and the forward scattering light pulse width in the forward scattering light signal of each particle in the to-be-tested sample. Therefore, accurate platelet counting can be obtained through one-time platelet optical detection.

The invention discloses a method, a device, equipment and a medium for predicting the reaching of pCR of neoadjuvant chemotherapy of triple negative breast cancer, and relates to the technical field of medical data processing, and the method comprises the following steps: obtaining clinical pathological characteristics of a to-be-detected object and peripheral blood counting data before neoadjuvant chemotherapy; the peripheral blood count data comprises neutrophil count, lymphocyte count, platelet count and mononuclear cell count; the clinical pathological characteristics comprise a T staging characteristic, an N staging characteristic and a Ki-67 characteristic; determining a target biomarker related to pathologic complete remission pCR prediction based on the peripheral blood count data, and calculating an immune inflammation score according to the target biomarker; the clinical pathological features and the immune inflammation scores are processed through a trained XGB model, and a pCR prediction result of the to-be-detected object is obtained; and the XGB model is used for capturing a nonlinear relationship and an interaction effect among the data. According to the invention, the problem of poor detection timeliness can be avoided, and the pCR prediction accuracy is improved at the same time.

This invention provides a platelet counting method that enables highly sensitive and stable platelet counting even after a significant amount of time has passed since blood collection. [Solution] A platelet counting method comprising bringing a collected blood sample 20 into contact with a substrate 12 having a platelet-solid phase portion 14 on its surface, and washing the substrate 12 to which the blood sample 20 has adhered while the platelets 26 contained in the blood sample 20 are solidified on the substrate 12.

The invention discloses a platelet, blood sugar and blood coagulation function joint detection chip, a detection device and a detection method, and belongs to the field of biomedical engineering. The invention discloses a platelet, blood sugar and blood coagulation function joint detection chip, a detection device and a detection method. The platelet, blood sugar and blood coagulation function joint detection chip comprises a micro-fluidic chip, a driving and control system, a detection and sensing system and a data processing and output system. The problems that in the prior art, key indexes such as platelet counting, blood sugar and blood coagulation functions need to depend on different devices, the process is tedious, consumed time is long, and the rapid diagnosis requirement of emergency treatment cannot be met due to step-by-step detection are solved, automatic separation and accurate distribution of whole blood samples are achieved through the integrated layered flow channel design, and the detection efficiency is improved. A multi-band optical detection and quantum dot fluorescence imaging technology is combined, and a multi-mode and high-sensitivity real-time signal acquisition system is established, so that multi-index automatic, parallel and rapid detection after whole blood sample injection is realized on a single chip platform, and the detection efficiency and the result reliability are greatly improved.

The invention provides a sample analysis system and method, and relates to the field of blood detection, and the system comprises: a first blood cell analysis device for detecting platelets in a blood sample based on an impedance method; the second blood cell analysis device is used for detecting platelets in the blood sample based on an optical method; a smear preparation device for preparing a blood smear from the blood sample; a cell image analysis device for acquiring and analyzing an image of a cell in the blood smear; the control device is used for acquiring a first platelet count value from the first blood cell analysis device; if the first platelet count value is judged to be subjected to abnormal interference, indicating a second blood cell analysis device to perform optical reinspection to obtain a second platelet count value; if it is judged that the first platelet count value is not subjected to abnormal interference and is out of the first preset range, the smear preparation device is indicated to prepare the to-be-detected blood smear, and the cell image analysis device is indicated to perform image method reinspection on the to-be-detected blood smear, so that the detection efficiency can be improved, and the detection cost can be reduced.

The invention relates to tinostamustine for use in the treatment of lymphoma or a T-cell malignant disease. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patients platelet count.

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.

Methods and materials that can be used to measure the concentration of platelets in whole blood samples (e.g., at the point of care) are provided herein.

The invention discloses an in-vitro sample detection data-based decompensated liver cirrhosis risk assessment method and a related device, and relates to the technical field of liver cirrhosis condition assessment. The method comprises the following steps: acquiring in-vitro detection sample data corresponding to a to-be-assessed blood sample, the in-vitro detection sample data comprises sCD146, prothrombin time, serum albumin and platelet count; performing data preprocessing on the in-vitro detection sample data, namely generating a serum albumin grade variable ALBgrade based on a preset grading threshold value according to the numerical value of the serum albumin; inputting the processed feature data into a pre-trained binary Logistic regression model, and outputting a decompensated liver cirrhosis risk value corresponding to the to-be-evaluated blood sample; the decompensated liver cirrhosis risk value is a prediction probability P output by the binary Logistic regression model. The method can effectively improve the evaluation accuracy of decompensated liver cirrhosis.

The application discloses an AI fusion enabled CRRT intelligent anticoagulation decision system, and relates to the technical field of intelligent control of medical equipment.The system comprises a data acquisition module, a data preprocessing module, an AI calculation module, a decision output module and a control interface module.The application constructs a hybrid AI model with fusion space and time sequence feature extraction capability, realizes multidimensional and dynamic precise modeling of the complex problem of CRRT anticoagulation decision, uses a convolutional neural network (CNN) to mine deep spatial correlation features among patient weight, coagulation indicators and platelet count static parameters, simultaneously uses a long short-term memory network (LSTM) to process high-frequency time sequences formed by transmembrane pressure and filter pressure machine parameters, and learns dynamic rules of filter performance attenuation and subtle trends of coagulation precursors from the time sequences, so that the system can generate an optimal parameter trajectory that is self-adaptively adjusted with the evolution of the system state based on the current instantaneous system state.

Use of a CD38 inhibitor for blocking mononuclear macrophage function in treating ITP. An anti-CD38 antibody serving as a CD38 inhibitor specifically binds to CD38 molecules on the membrane surface of mononuclear macrophages to inhibit the proliferation of mononuclear macrophages, reducing the number and proportion of mononuclear macrophages, effectively inhibiting the ADCC effect, and rapidly improving platelet counts in patients. The inhibitor can be used for treating various types of ITP patients, and the effective rate in treating ITP is high.

Apparatus and methods are provided including imaging a blood sample that is a cell suspension deposited in a sample chamber. The cells are allowed to settle in the sample chamber to form a monolayer of cells. At least one microscopic image is acquired of the monolayer of cells using a microscope (24) while the microscope is focused at a monolayer-depth-level, and a first platelet count of platelets that have settled within the monolayer, is determined. An additional microscopic image of the simple is acquired, while the microscope is focused at a different depth level from the monolayer-depth-level, and a second platelet count of platelets that have not settled within the monolayer is determined. An output is generated based upon the first and second platelet counts. Other applications are also described.

The embodiment of the invention provides a children sirolimus administration dosage prediction method, equipment, a medium and a program product, and relates to the field of intelligent medical treatment. The method comprises the following steps: acquiring prediction parameter information of a to-be-detected sample, wherein prediction parameters comprise weight, age, platelet count and creatinine; inputting the prediction parameter information into the dose prediction model, and calculating the predicted dose of sirolimus; the predicted dose is the daily average dose in the stable treatment period. The application develops an administration dosage prediction model aiming at three clinical problems of dosage error caused by development dynamics, high-risk group medication risk and passive decision mode in children sirolimus administration.